Rapid and efficient production of radiolabeled antibody conjugates using vacuum diafiltration guided by mathematical modeling.
Increasing interest in the use of radiolabeled antibodies for cancer imaging and therapy drives the need for more efficient production of the antibody conjugates. Here, we illustrate a method for rapid and efficient production of radiolabeled antibody conjugates using vacuum diafiltration guided by mathematical modeling. We apply this technique to the production of 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA)-conjugated antibodies at the milligram and gram production scale and achieve radiolabeling efficiencies >95% using In-111. Using vacuum diafiltration, antibody-chelate conjugation and purification can be accomplished within the same vessel, and the entire process can be completed in <24 h. Vacuum diafiltration also offers safer and gentler processing conditions by eliminating the need to keep the retentate vessel under positive pressure through applied gas pressure or shear-inducing restriction points in the retentate flow path. Experimental data and mathematical model calculations suggest there exists a weak binding affinity (approximately 10(4)M(-1)) between the charged chelate molecules (e.g., DOTA) and the antibodies that slows the removal of excess chelate during purification. By analyzing the radiolabeling efficiency as a function of the number of diavolumes, we demonstrate the importance of balancing the removal of free chelate with the introduction of metal contaminants from the diafiltration buffer and also illustrate how to optimize radiolabeling of antibody conjugates under a variety of operating conditions. This methodology is applicable to the production of antibody conjugates in general.
Bartlett
Derek W
DW
Division of Cancer Immunotherapeutics & Tumor Immunology, Beckman Research Institute and City of Hope National Medical Center, Duarte, California 91010, USA.
Colcher
David
D
Raubitschek
Andrew A
AA
D000818:Animals; D000911:Antibodies, Monoclonal; D002614:Chelating Agents / Q000737:chemistry; D005374:Filtration / Q000379:methods*; D006573:Heterocyclic Compounds, 1-Ring / Q000737:chemistry*; D006801:Humans; D018796:Immunoconjugates / Q000737:chemistry*; D007553:Isotope Labeling / Q000379:methods*; D008962:Models, Theoretical; D016499:Radioimmunotherapy / Q000379:methods*; D019275:Radiopharmaceuticals / Q000737:chemistry*; D014618:Vacuum
D000911:Antibodies, Monoclonal; D002614:Chelating Agents; D006573:Heterocyclic Compounds, 1-Ring; D018796:Immunoconjugates; D019275:Radiopharmaceuticals; C071349:1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acid